Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study

  • Anja Kaeberich
  • Iris Reindl
  • Uwe Raaz
  • Lars Maegdefessel
  • Alexander Vogt
  • Torsten Linde
  • Ulrich Steinseifer
  • Elisabeth Perzborn
  • Baerbel Hauroeder
  • Michael Buerke
  • Karl Werdan
  • Axel Schlitt
Article

Abstract

Thromboembolism and bleeding after mechanical heart valve replacement are still unsolved problems, particularly for patients requiring anticoagulative bridging therapy. The aim of this study was to investigate whether rivaroxaban, a new oral selective and direct coagulation factor Xa inhibitor, is as effective as enoxaparin and unfractionated heparin (UFH) in preventing thrombus formation on mechanical heart valves using an in vitro system. Blood from healthy male donors was anticoagulated with either UFH, enoxaparin, rivaroxaban at 300 ng/ml, (n = 10 each), or rivaroxaban at 30 ng/ml (n = 3). Mechanical aortic valve prostheses were placed into the in vitro testing system THIA II and exposed to the anticoagulant blood mixtures at a pulsatile flow for 60 min. Overall thrombus weight, coagulation parameters, and electron microscopic features of thrombus formation on the valve surface were quantified as endpoints. The mean thrombus weights were 163 ± 64 mg for group 1 (UFH), 341 ± 63 mg for the group 2 (enoxaparin), 238 ± 83 mg for group 3 (rivaroxaban 300 ng/ml) and 1.739 ± 16 mg for group 4 (rivaroxaban 30 ng/ml). Whereas high-dosed rivaroxaban showed no significant differences compared to UFH or enoxaparin, low-dosed rivaroxaban generated a massive thrombus generation, thus differing significantly from all other treatment groups regarding the thrombus weight. We hypothesize that high-dose rivaroxaban is a competitive oral available alternative to UFH and LMWH’s, that might be a worthwhile alternative for patients in need of anticoagulative bridging therapy. Prospective studies have to evaluate if rivaroxaban might even overcome the limitations of OAC in patients after implantation of artificial heart valves.

Keywords

Anticoagulation Rivaroxaban Mechanical heart valves Thrombosis 

Notes

Acknowledgments

This study was funded by an unrestricted grant from BAYER-Schering® Pharma.

Conflicts of interest

Mrs. Elisabeth Perzborn is an employee of Bayer HealthCare®.

References

  1. 1.
    Cannegieter SC, Rosendaal FR, Briët E (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635–641PubMedGoogle Scholar
  2. 2.
    Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, Barbui T (1993) Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Heamost 69:316–320Google Scholar
  3. 3.
    Palareti G, Hirsh J, Legnani C, Manotti C, D’Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S (2000) Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 160(4):470–478PubMedCrossRefGoogle Scholar
  4. 4.
    Stöllberger C, Finsterer J, Länger T, Schneider B, Wehinger C, Hopmeier P, Slany J (2002) Problems, interventions and complications in long-term oral anticoagulation therapy. J Thromb Thrombolysis 14(1):65–72PubMedCrossRefGoogle Scholar
  5. 5.
    Palareti G, Leali N, Poggi SCM, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428PubMedCrossRefGoogle Scholar
  6. 6.
    Koerfer R, Reiss N, Koertke H (2009) International normalized ratio patient self-management for mechanical valves: is it safe enough? Curr Opin Cardiol 24(2):130–135PubMedCrossRefGoogle Scholar
  7. 7.
    Bonow RO, Carabello BA, Chatterjee K, de Leon ACJR, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2008) 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52(13):1–142CrossRefGoogle Scholar
  8. 8.
    Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Task force on the management of valvular hearth disease of the European Society of Cardiology; ESC committee for practice guidelines (2007) Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28(2):230–268PubMedCrossRefGoogle Scholar
  9. 9.
    Greinacher A, Althaus K, Krauel K, Selleng S (2010) Heparin-induced thrombocytopenia. Hamostaseologie 30(1):17–18 20-8PubMedGoogle Scholar
  10. 10.
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, American College of Chest Physicians (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl):141S–159SPubMedCrossRefGoogle Scholar
  11. 11.
    Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler–Soler J (2003) Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocoumarol. Heart 89(5):527–530PubMedCrossRefGoogle Scholar
  12. 12.
    Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D (2000) Low molecular weight heparin after mechanical heart valve replacement. Circulation 101(10):1083–1086PubMedGoogle Scholar
  13. 13.
    Dunn A, Turpie A (2003) Perioperative management of patients reviving oral anticoagulants: a systematic overview. Arch Intern Med 163:901–908PubMedCrossRefGoogle Scholar
  14. 14.
    Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A, Petersen H, REGIMEN Investigators (2008) Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 102(7):883–889PubMedCrossRefGoogle Scholar
  15. 15.
    Schlitt A, Hamilton K, Maegdefessel L, Dahm M, Theis C, Eichler M, Brockmann O, Steinseifer U, Hauroeder B, Hitzler WE, Rupprecht HJ (2006) Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Heart Valve Dis 15(6):809–814PubMedGoogle Scholar
  16. 16.
    Maegdefessel L, Linde T, Michel T, Hamilton K, Steinseifer U, Friedrich I, Schubert S, Hauroeder B, Raaz U, Buerke M, Werdan K, Schlitt A (2009) Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves Results of an in vitro study. Thromb Haemost 101(6):1163–1169PubMedGoogle Scholar
  17. 17.
    Maegdefessel L, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K, Schlitt A (2010) In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res 126(3):e196–e200PubMedCrossRefGoogle Scholar
  18. 18.
    Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100(3):453–461PubMedGoogle Scholar
  19. 19.
    Dasi LP, Simon HA, Sucosky P, Yoganathan AP (2009) Fluid mechanics of artificial heart valves. Clin Exp Pharmacol Physiol 36:225–237PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang P, Yeo JH, Qian P, Hwang NH (2007) Shear stress investigation across mechanical heart valve. ASAIO J 53:530–536PubMedCrossRefGoogle Scholar
  21. 21.
    Smith CJ, Vournakis JN, Demcheva M, Fischer TH (2008) Differential effect of materials for surface hemostasis on red blood cell morphology. Microsc Res Tech 71:721–729PubMedCrossRefGoogle Scholar
  22. 22.
    Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514–521PubMedCrossRefGoogle Scholar
  23. 23.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412–421PubMedCrossRefGoogle Scholar
  24. 24.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2007) Rivaroxaban (BAY 59–7939)–an oral, direct Factor Xa inhibitor–has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 63(4):469–476PubMedCrossRefGoogle Scholar
  25. 25.
    Kubitza D, Becka M, Voith B (2005) Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(Suppl 1):P1704Google Scholar
  26. 26.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(5):549–558PubMedCrossRefGoogle Scholar
  27. 27.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) No interaction between the novel, oral direct Factor Xa inhibitor BAY 59–7939 and digoxin. J Clin Pharmacol 46: 702 (Abstract 11)Google Scholar
  28. 28.
    Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 37(5):1056–1064PubMedCrossRefGoogle Scholar
  29. 29.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. Blood 108: Abstract 905Google Scholar
  30. 30.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47(2):218–226PubMedCrossRefGoogle Scholar
  31. 31.
    Halabi A, Kubitza D, Zuehlsdorf M, Becka M, Mueck W, Maatouk H (2007) Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban—an oral, direct Factor Xa inhibitor. J Thromb Haemost 5(Suppl 2): Abstract P-M-635Google Scholar
  32. 32.
    Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O, Messmore HL, Bakhos M (2008) Rivaroxaban–an oral, direct Factor Xa inhibitor–has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 143(1):92–99PubMedCrossRefGoogle Scholar
  33. 33.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thrombo prophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775PubMedCrossRefGoogle Scholar
  34. 34.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39PubMedCrossRefGoogle Scholar
  35. 35.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786PubMedCrossRefGoogle Scholar
  36. 36.
    Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 investigators (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680PubMedCrossRefGoogle Scholar
  37. 37.
    Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, ATLAS ACS-TIMI Gibson CM 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29–38PubMedCrossRefGoogle Scholar
  38. 38.
    Becker R, Berkowitz SD, Breithardt G, Califf RM, Fox K, Hacke W, Halperin J, Hankey G, Mahaffey K, Nessel C, Singer D, Ardissino D, Avezum A, Aylward P, Biedermann B, Breithardt G, Bode C, Carolei A, Corbalán R, Csiba L (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347CrossRefGoogle Scholar
  39. 39.
    Samama MM, Martinoli J, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E (2010) Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anja Kaeberich
    • 1
  • Iris Reindl
    • 1
  • Uwe Raaz
    • 1
  • Lars Maegdefessel
    • 2
  • Alexander Vogt
    • 1
  • Torsten Linde
    • 3
  • Ulrich Steinseifer
    • 3
  • Elisabeth Perzborn
    • 4
  • Baerbel Hauroeder
    • 5
  • Michael Buerke
    • 1
  • Karl Werdan
    • 1
  • Axel Schlitt
    • 1
  1. 1.Department of Internal Medicine IIIMartin Luther-University Halle-WittenbergHalleGermany
  2. 2.Department of Cardiovascular MedicineStanford UniversityStanfordUSA
  3. 3.Department of Cardiovascular EngineeringInstitute of Applied Medical Engineering, Helmholtz Institute, RWTH Aachen UniversityAachenGermany
  4. 4.Bayer Schering Pharma AGWuppertalGermany
  5. 5.Central Institute of the German Federal Armed ForcesKoblenzGermany

Personalised recommendations